Abstract
China’s pharmaceutical market has experienced significant growth in recent years, fueled by increasing wealth among its own population as well as accelerating global demand for cheap, effective medicines to treat ailments ranging from high cholesterol to HIV/AIDS. Along with India, China supplies more than 40 percent of the active pharmaceutical ingredients (API) used to make U.S. pharmaceuticals. The current financial crisis, and the limited resources and tighter budgets it has engendered, may accelerate the trend. Yet, China is dogged by a history of poor-quality pharmaceuticals that have killed hundreds and sickened thousands of its own citizens and people across the globe. The government has begun to tighten its laws, but enforcement remains weak, and official obfuscation is rampant. While any retaliatory protectionist measures in the United States would be counterproductive, China and its international partners would gain from improving the frequency and technical sophistication of inspections, the prosecution of perpetrators, and the culture of self-policing within China’s pharmaceutical industry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
